Home » Topics » BioWorld Science

BioWorld Science
RSS

Imbruvica approved in Japan for untreated CLL

July 4, 2018

Kalyra Pharmaceuticals patents amphotericin B derivatives as antifungals

July 4, 2018

Anavex cleared to begin phase IIb/III study of Anavex 2-73 for early Alzheimer's disease

July 4, 2018

Bionomics presents new nicotinic alpha7 receptor antagonists

July 4, 2018

Catalent to acquire Juniper Pharmaceuticals

July 4, 2018

Photo-controlled adenosine A2A receptor antagonist may help in the management of Parkinson's disease

July 4, 2018

JCR initiates phase III trial of JR-401X for SHOX deficiency

July 4, 2018

Updated data for phase I/II study of BMS-986205 plus nivolumab in advanced bladder cancer

July 4, 2018

Diagnogreen receives approval for additional indication and dosage in Japan

July 4, 2018

Trerief approved in Japan for additional indication

July 4, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
HMNC raises $50M series B to prep depression drugs for phase III
BioWorld
HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...